CHLORPHENAMINE

DRUG3 trials

Sponsors

Lytix Biopharma AS, Azienda Provinciale Per I Servizi Sanitari, Fondazione Gimema Franco Mandelli Onlus

Conditions

Advanced MelanomaVery High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)prostate cancer

Phase 2

A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy

CompletedCTIS2022-500628-31-00

Lytix Biopharma ASAdvanced Melanoma

Start: 2022-10-24End: 2025-06-13Target: 22Updated: 2024-03-11

Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)- GIMEMA ALL3024

RecruitingCTIS2024-511627-34-00

Fondazione Gimema Franco Mandelli OnlusVery High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL)

Start: 2024-10-17Target: 31Updated: 2025-12-23

Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts

Not yet recruitingCTIS2023-503676-25-01

Azienda Provinciale Per I Servizi Sanitariprostate cancer

Target: 157Updated: 2024-11-18

Related Papers

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Blood2024-11-05